The latest Ipsos MORI Asthma UK survey, this year part funded by Merck Sharp & Dohme, the local subsidiary of US drug major Merck & Co, found that over two thirds (67%) of the 1,235 respondents diagnosed with asthma also suffered from symptoms of allergic rhinitis (hay fever) including runny nose, sneezing or itchy or red eyes. In addition, 72% of those said their asthma became worse when they experienced allergic rhinitis symptoms. These findings support the increasing recognition that asthma and allergic rhinitis are associated conditions.
Asthma and allergic rhinitis commonly co-exist and both cause inflammation of the airway. Previous research has reported that at least 50% of asthma patients also suffer from allergic rhinitis. Research also shows that the presence of allergic rhinitis increases the risk of asthma attacks and emergency hospitalization. However, 65% of survey respondents with allergic rhinitis symptoms said that their health care professional (doctor, nurse or pharmacist) had never discussed the condition's impact on asthma control.
For the majority of people surveyed (84%), symptoms were most severe during the spring or summer months, when pollen levels are high and hay fever is more prominent. However, 20% of respondents experience allergic rhinitis symptoms all year round, suggesting that people with asthma need to regularly monitor their symptoms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze